Molecular Partners AG Files 6-K for Q2 2024
Ticker: MOLN · Form: 6-K · Filed: Aug 26, 2024 · CIK: 1745114
Sentiment: neutral
Topics: 6-K, financials, reporting
TL;DR
Molecular Partners AG dropped its Q2 2024 6-K, check financials.
AI Summary
Molecular Partners AG filed a 6-K report for the period ending June 30, 2024. The filing provides financial information and details related to the company's operations. Specific financial figures and operational updates are contained within the full report.
Why It Matters
This filing provides investors with an update on Molecular Partners AG's financial status and operational developments as of the second quarter of 2024.
Risk Assessment
Risk Level: low — This is a routine 6-K filing providing financial updates, not a significant event like an acquisition or major clinical trial result.
Key Players & Entities
- MOLECULAR PARTNERS AG (company) — Filer
- 20240630 (date) — Period of Report
- 20240826 (date) — Filing Date
FAQ
What is the reporting period for this 6-K filing?
The conforming period of report is 20240630, meaning the filing covers information up to June 30, 2024.
When was this 6-K filing submitted to the SEC?
This filing was submitted on 20240826.
What is the company's primary business classification?
The company is classified under BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) with SIC code 2836.
Where is Molecular Partners AG located?
The company's business address is Wagistrasse 14, Zurich-Schlieren, Switzerland, ZIP 8952.
What is the SEC file number for this company?
The SEC file number for Molecular Partners AG is 001-40488.
Filing Stats: 414 words · 2 min read · ~1 pages · Grade level 13.1 · Accepted 2024-08-26 16:00:39
Filing Documents
- moln-20240630.htm (6-K) — 43KB
- sec_prh12024991.htm (EX-99.1) — 62KB
- sec_h12024strategicupdatef.htm (EX-99.2) — 103KB
- moln-20240630_d2.htm (EX-99.3) — 300KB
- image_0a.jpg (GRAPHIC) — 48KB
- moln-20240630_g1.jpg (GRAPHIC) — 12KB
- moln-20240630_g2.jpg (GRAPHIC) — 45KB
- moln-20240630_g3.jpg (GRAPHIC) — 4KB
- 0001745114-24-000017.txt ( ) — 2754KB
- moln-20240630.xsd (EX-101.SCH) — 33KB
- moln-20240630_cal.xml (EX-101.CAL) — 61KB
- moln-20240630_def.xml (EX-101.DEF) — 49KB
- moln-20240630_lab.xml (EX-101.LAB) — 266KB
- moln-20240630_pre.xml (EX-101.PRE) — 179KB
- moln-20240630_htm.xml (XML) — 253KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Molecular Partners AG (Registrant) Date: August 26, 2024 /s/ PATRICK AMSTUTZ Name: Patrick Amstutz Title: Chief Executive Officer